Cardioprotection with pioglitazone is abolished by nitric oxide synthase inhibitor in ischemic rabbit hearts - Comparison of the effects of pioglitazone and metformin

Diabetes/Metabolism Research and Reviews

Volumn 19, Issue 4, 2003, Pages 299-305

  Kawabata, Hitoshi ^a   Ishikawa, Kinji ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardioprotection; Ischemia; Metformin; Nitric oxide; Pioglitazone

Indexed keywords

ADENOSINE TRIPHOSPHATE; METFORMIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PIOGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; DRUG ANTAGONISM; ENERGY METABOLISM; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HIGH ENERGY PHOSPHATE; ISOLATION PROCEDURE; MALE; NONHUMAN; PHOSPHATE METABOLISM; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; RABBIT;

ADENOSINE TRIPHOSPHATE; ANIMALS; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; ENZYME INHIBITORS; HEART; HYPOGLYCEMIC AGENTS; KINETICS; METFORMIN; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PHOSPHATES; RABBITS; THIAZOLIDINEDIONES;

EID: 0042093506     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.379     Document Type: Article

References (48)

1. Ikeda H, Taketomi S, Sugiyama Y, et al. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneim-Forsh/Drug Res 1990; 40: 156-162.
2. Hofmann CA, Colca JR. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care 1992; 15: 1075-1078.
3. Koshiyama H, Shimono D, Kuwamura N, Minamikawa, J, Nakamura Y. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3452-3456.
4. Dubey RK, Zhang HY, Reddy SR, Boegehold MA, Kotchen TA. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am J Physiol 1993; 265: R726-R732.
5. Peuler JD, Phare MP, Iannucci AR, Hodorek MJ. Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle cell proliferation. Am J Hypertens 1996; 9: 188-192.
6. Yoshimoto T, Naruse M, Shizumi H, et al. Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. Atherosclerosis 1999; 145: 333-340.
7. Igarashi M, Hirata A, Yamaguchi H, et al. Characterization of an inhibitory effect of pioglitazone on balloon-injured vascular smooth muscle cell growth. Metabolism 2001; 50: 955-962.
8. Fukunaga Y, Itoh H, Doi K, et al. Thiazolidinediones, peroxisome proliferator-activated receptor γ agonists, regulate endothelial cell growth and secretion of vasoactive peptides. Atherosclerosis 2001; 158: 13-119.
9. Sugawara A, Takeuchi K, Uruno A, et al. Hypertens Res 2001; 24: 229-233.
10. Kotchen TA, Reddy S, Zhang HY. Increasing insulin sensitivity lowers blood pressure in the fructose-fed rat. Am J Hypertens 1997; 10: 1020-1026.
11. Aizawa Y, Kawabe J, Hasebe N, Takehara N, Kikuchi K. Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia. Circulation 2001; 104: 455-460.
12. Kotchen TA. Attenuation of hypertension by insulin-sensitizing agents. Hypertension 1996; 28: 219-223.
13. United Kingdom Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
14. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
15. Bhalla RC, Toth KF, Tan E, Bhatty RA, Mathias BE, Sharma RV. Vascular effects of metformin: possible mechanisms for its antihypertensive action in the spontaneously hypertensive rat. Am J Hypertens 1996; 9: 570-576.
16. Marfella R, Acampora R, Verrazzo G, et al. Metformin improves hemodynamic and rheological responses to L-arginine in NIDDM patients. Diabetes Care 1996; 19: 934-939.
17. Katakam PVG, Ujhelyi MR, Hoenig M, Miller AW. Metformin improves vascular function in insulin-resistant rats. Hypertension 2000; 35: 108-112.
18. Kawabata H, Ishikawa K. Cardioprotection with metformin is abolished by nitric oxide synthase inhibitor in ischemic rabbit hearts. Hypertens Res 2003; 26: 107-110.
19. Hiraga K. Study of AD-4833 in clinical practice by phase I (in Japanese). Jan J Clin Exp Med 1997; 74: 1184-1201.
20. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996; 30: 359-371.
21. G-nitro-L-arginine methyl ester in conscious, Long Evans rats. Br J Pharmacol 1990; 101: 625-631.
22. 31P nuclear magnetic resonance analysis of metabolite concentrations in Langendorff-perfused rabbit hearts. Biophys J 1985; 48: 803-813.
23. Moncada S, Palmer RMJ, Higgs EA. Biosynthesis of nitric oxide from L-arginine. A pathway for the regulation of cell function and communication. Biochem Pharmacol 1989; 38: 1709-1715.
24. G-nitro arginine (L-NOARG), a novel, L-arginine-reversible inhibitor of endothelium-dependent vasodilatation in vitro. Br J Pharmacol 1990; 99: 408-412.
25. Node K, Kitakaze M, Kosaka H, et al. Plasma nitric oxide end products are increased in the ischemic canine heart. Biochem Biophys Res Commun 1995; 211: 370-374.
26. Opie LH. The Heart Physiology, Metabolism, Pharmacology and Therapy, Grune & Stratton: London, 1984; 351-371.
27. Kawabata H, Nakagawa K, Ishikawa K. A novel cardioprotective agent, JTV-519, is abolished by nitric oxide synthase inhibitor on myocardial metabolism in ischemia-reperfused rabbit hearts. Hypertens Res 2002; 25: 303-309.
28. Jennings RB, Reimer KA. Lethal myocardial ischemic injury. Am J Pathol 1981; 102: 241-255.
29. Kawabata H, Ryomoto T, Ishikawa K. Effect of beta-blocker on metabolism and contraction of doxorubicin-induced cardiotoxicity in the isolated perfused rabbit heart. Angiology 2000; 21: 405-413.
30. Ikeda S, Watanabe T. Effects of troglitazone and pioglitazone on the action potentials and membrane currents of rabbit ventricular myocytes. Eur J Pharmacol 1998; 357: 243-250.
31. Isshiki K, Haneda M, Koya D, Maeda S, Sugimoto T, Kikkawa R. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 2000; 49: 1022-1032.
32. Force T, Bonventre JV. Growth factors and mitogen-activated protein kinases. Hypertension 1998; 31: 152-161.
33. Laufs U, Endres M, Stagliano N, et al. Neuroprotection mediated by changes in the endothelial action cytoskeleton. J Clin Invest 2000; 106: 15-24.
34. Nakanishi K, Vinten-Johansen J, Lefer DJ, et al. Intracoronary L-arginine during reperfusion improves endothelial function and reduces infarct size. Am J Physiol 1992; 263: H1650-H1658.
35. Benjamin IJ, McMillan DR. Stress (heat shock) proteins: molecular chaperones in cardiovascular biology and disease. Circ Res 1998; 83: 117-132.
36. Vegh A, Szekeres L, Parratt J. Preconditioning of the ischaemic myocardium: involvement of the L-arginine nitric oxide pathway. Br J Pharmacol 1992; 107: 648-652.
37. 2+ channels by S-nitrosothial nitric oxide donors. Circ Res 1997; 81: 742-752.
38. Sasaki N, Sato T, Ohler A, O'Rourke B, Marban E. Activation of mitochondrial ATP-dependent potassium channels by nitric oxide. Circulation 2000; 101: 439-445.
39. Gross GJ, Auchanpach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 1992; 70: 223-233.
40. 1 receptors. Circulation 1992; 86: 1310-1316.
41. Kawabata H, Ryomoto T, Ishikawa K. Role of cardiac ATP-sensitive K+ channels induced by HMG CoA reductase inhibitor in ischemic rabbit heart. Hypertens Res 2001; 24: 573-577.
42. Kawabata H, Nakagawa K, Ishikawa K. Effects of an HMG-CoA reductase inhibitor in combination with an ACE inhibitor or angiotensin II type 1 receptor antagonist on myocardial metabolism in ischemic rabbit hearts. Hypertens Res 2002; 25: 203-210.
43. + channels modulate cardiac mitochondrial function. Am J Physiol 1998; 275: H1567-H1576.
44. Shiomi T, Tsutsui H, Hayashidani S, et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002; 106: 3126-3132.
45. Mizushige K, Tsuji T, Noma T. Pioglitazone: cardiovascular effects in prediabetic patients. Cardiovasc Drug Rev 2002; 20: 329-340.
46. Charlon V, Boucher F, Mouhieddine S, Leiris JD. Reduction of myocardial infarct size by metformin in rats submitted to permanent left coronary artery ligation. Diabetes Metab 1988; 14: 591-595.
47. 2+ transients in adult rat ventricular myocytes. Diabetes 1999; 48: 2059-2065.
48. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-1174.